Advanced Squamous Non-Small Cell Lung Carcinoma
4
1
2
0
Key Insights
Highlights
Treatment Research
12 treatments under study, led by Pembrolizumab
Research Leaders
5 sponsors active, led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 4 trials
25%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (4)
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
Research Network
Common Treatments
- Pembrolizumab2
- Anlotinib Hydrochloride Capsule1
- Tqb24501
- Platinum Chemotherapy Carboplatin Or Cisplatin1
- Docetaxel1
Active Sponsors
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1
- Newsoara Biopharma Co., Ltd.1
- Roswell Park Cancer Institute1
- Ribon Therapeutics, Inc.1
- Genelux Corporation1
Top Investigators
Tennessee Oncology
Roswell Park Cancer Institute
Related Conditions
- Recurrent Head And Neck Squamous Cell Carcinoma1
- Stage Iva Lung Cancer Ajcc V81
- Advanced Head And Neck Squamous Cell Carcinoma1
- Stage Iv Lung Cancer Ajcc V81
- Stage Ivb Lung Cancer Ajcc V81